Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibody composition for leukemia/lymphoma immunotyping preliminary screening and application thereof

An immunophenotyping and composition technology, which is applied in the field of antibody composition for the primary screening of leukemia/lymphoma immunophenotyping, can solve the problems of insufficient antibody combination, waste of antibodies, lack of antibodies, etc., and reduce the overall process and time. , for enhanced precision and specificity

Active Publication Date: 2021-12-10
PEOPLES HOSPITAL PEKING UNIV
View PDF17 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The disadvantage is that there is a lack of antibodies with the strongest specificity, such as intracellular cCD3, cCD79, cCD22, cMPO, and the clonality markers of B cells and T cells: kappa / lambda, TRBC1. Misjudgment is inevitable, and further research is needed. The third step of detection is a waste of antibodies and a waste of time
[0011] Therefore, the antibody combination in the prior art cannot reach the purpose of comprehensively and accurately diagnosing acute and chronic leukemia and lymphoma with a single tube. At present, it is necessary to design a comprehensive, accurate, economical and efficient immunophenotyping of blood tumors ( Especially the antibody combination of primary screening) solves practical clinical difficulties and benefits patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody composition for leukemia/lymphoma immunotyping preliminary screening and application thereof
  • Antibody composition for leukemia/lymphoma immunotyping preliminary screening and application thereof
  • Antibody composition for leukemia/lymphoma immunotyping preliminary screening and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] The preparation of embodiment 1 reagent

[0077]This example uses the antibody combination as follows, the membrane antibody includes: CD38-BV785, CD3-BV750, CD10-BV711, CD33-BV650, CD5-BV605, CD19-BV421, CD45-BV510, CD56-PE-Fire700, CD7-APC- Fire750, CD117-PE-Cy5, CD34-PE-Cy7, TRBC1-PE; Intrabodies include: cCD22-APC, cCD3-Alexa Fluor647, cCD79a-PE, cLampda-PE-Dazzle594, nTdT-FITC, cKappa-Alexa Fluor 700, cMPO-eFluor 450, these antibodies can be directly purchased commercially, and the antibodies of the embodiment of the present invention are purchased from BD, Biolegend, Beckman, and Thermo.

[0078] The above-mentioned 19 kinds of quantitative antibodies were divided into 2 parts according to the membrane and intracellular antibodies, mixed and packed in 2 containers respectively, and used for immunophenotyping and labeling of samples.

[0079] The kit for detecting leukemia and lymphoma typing also includes erythrocyte lysate and PBS, and the erythrocyte lysate can...

Embodiment 2

[0080] Example 2 18-color flow cytometry analysis of leukemia / lymphoma disease immunophenotype

[0081] 1. The main materials and instruments of the experiment

[0082] (1) Materials: 10×PBS buffer, hemolysin for flow cytometry (BD Company);

[0083] (2) Instrument: CytekNL-3000 model full-spectrum flow cytometer, equipped with three lasers of 405nm, 488nm and 635nm, and 38 fluorescence detectors. Desktop low-speed centrifuge, vortex mixer.

[0084] 2. Method

[0085] 2.1 Sample collection:

[0086] Immediately place 1-3mL of the obtained human bone marrow fluid into a heparin anticoagulant tube and quickly invert it several times to prevent the sample from coagulating. For various cells such as pleural effusion and lavage fluid, they should be sent to the laboratory as soon as possible after collection, and the samples should be placed in Store refrigerated at 4°C. The flow cytometry (FCM) test must be completed within 48 hours and operated according to the instructions....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a reagent composition for leukemia / lymphoma typing. The reagent composition comprises 19 kinds of antibodies. According to the optimized antibody combination, the fluorescence labeling combination of the corresponding antibody and the result interpretation method, the AML, the ALL-B, the ALL-T, the MPAL, the NHL-B, the NHL-T, the PCN, the NHL-NK and the chronic myeloid tumors can be preliminarily screened comprehensively and efficiently only by using 19 antibodies and one-tube cell one-time sample loading, and the aim of clearly diagnosing the AML, the ALL-B, the ALL-T, the MPAL, the NHL-B, the NHL-T and the PCN is achieved. The 19 antibody combinations are used for analyzing the expression of tumor cell antigens in a sample, and leukemia-related immunophenotypes (LAIP) which can be used for monitoring post-treatment trace residual disease (MRD) in the antibody combinations are determined.

Description

technical field [0001] The present invention relates to the field of antibody medicine, in particular to an antibody composition for primary screening of leukemia / lymphoma immunotype and its application. Background technique [0002] Leukemia and lymphoma are malignant tumors of the hematopoietic system, and their differentiation is blocked at different stages to form corresponding subtypes. There are many clinical classifications of leukemia and lymphoma. The 2017 edition of WHO's classification of tumors of the blood and lymphatic system mainly includes acute myeloid leukemia (AML) and related myeloid precursor cell tumors (Table 1), and precursor lymphoid tumors: Including B lymphoblastic leukemia / lymphoma (B-ALL / LBL), T lymphoblastic leukemia / lymphoma (T-ALL / LBL), acute serial leukemia (MPAL): including T / myeloid, B / myeloid Mixed et al, chronic myeloid neoplasms (Table 2), mature B cell neoplasms, mature T and NK cell neoplasms, Hodgkin lymphoma (HL), immunodeficiency-a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N33/577G01N33/574G01N33/58G01N15/14
CPCG01N33/6893G01N33/6872G01N33/577G01N33/57426G01N33/57407G01N33/57484G01N33/582G01N15/14G01N2015/1486
Inventor 刘艳荣王亚哲
Owner PEOPLES HOSPITAL PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com